此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Real-world Evidence With Long-Acting User-optimized Growth Hormone Therapy in Pediatric Growth Hormone Deficiency (REAL-LAUGH)

2026年11月10日 更新者:Fundació Sant Joan de Déu

The REAL-LAUGH study will compare changes in body composition and other health outcomes in children and adolescents with growth hormone deficiency who start weekly or daily growth hormone treatment in routine clinical practice in Spain.

Approximately 110 participants aged 3 to 16 years will be enrolled: 55 receiving weekly long-acting growth hormone and 55 receiving daily recombinant human growth hormone. The treating physician will select treatment as part of usual care, independently of study participation. The study will not assign treatment.

Participants will be followed for 12 months, with assessments at baseline, 6 months, and 12 months. The main outcome is the change in percentage total body fat measured by dual-energy X-ray absorptiometry, also called DXA, between baseline and 12 months. The study will assess whether the reduction in body fat with weekly treatment differs from that with daily treatment.

Other assessments will include lean body mass, growth, waist measurements, blood pressure, glucose and lipid metabolism, carotid artery wall thickness, bone mineral density, pubertal development, bone age, IGF-1 concentrations, and adverse events. No biological samples will be stored for research.

研究概览

研究类型

观察性的

注册 (估计的)

110

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Marta Ramon Krauel, MD PhD
  • 电话号码:71702 +34 932 804 000
  • 邮箱:marta.ramon@sjd.es

学习地点

      • Santiago de Compostela、西班牙
    • Barcelona
      • Barcelona、Barcelona、西班牙、08950
        • Hospital Sant Joan de Déu
        • 接触:
          • Marta Ramon Krauel, MD PhD
          • 电话号码:71702 +34 932 804 000
          • 邮箱:marta.ramon@sjd.es
    • Madrid
      • Madrid、Madrid、西班牙
    • Valencia
      • Valencia、Valencia、西班牙
    • Zaragoza
      • Zaragoza、Zaragoza、西班牙
        • Hospital Universitario Miguel Servet
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

3年 至 16年 (孩子)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Children and adolescents aged 3 to 16 years with growth hormone deficiency who attend participating pediatric endocrinology departments in Spain and are initiating either weekly long-acting growth hormone or daily recombinant human growth hormone in routine clinical practice. Eligible candidates will be identified during routine clinical visits and invited to participate.

描述

Inclusion Criteria:

  • Age between 3 and 16 years.
  • Diagnosis of growth hormone deficiency according to standard clinical practice in Spain and the applicable Spanish Ministry of Health criteria.
  • Growth hormone treatment approved by the relevant local authorities and institution.
  • Initiation of treatment with long-acting growth hormone or daily recombinant human growth hormone.

Exclusion Criteria:

- Recombinant human growth hormone prescribed for an indication other than growth hormone deficiency.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
Weekly Long-Acting Growth Hormone

Children and adolescents with growth hormone deficiency initiating once-weekly somatrogon as prescribed in routine clinical practice. Treatment selection, initiation, dosing, and subsequent modifications are determined by the treating physician independently of study participation.

LAGH administered by subcutaneous injection once weekly as part of routine clinical care. Prescribed doses and dose adjustments will be determined by the treating physician and recorded by the study. Treatment is not assigned by the protocol.

其他名称:
  • 生长激素
  • NGENLA
Daily Recombinant Human Growth Hormone

Children and adolescents with growth hormone deficiency initiating daily somatropin as prescribed in routine clinical practice. Treatment selection, initiation, dosing, and subsequent modifications are determined by the treating physician independently of study participation.

Human recombinant growth hormone administered by daily subcutaneous injection as part of routine clinical care. Prescribed products, doses, and dose adjustments will be determined by the treating physician and recorded by the study. Treatment is not assigned by the protocol.

其他名称:
  • 生长激素
  • 去甲肾上腺皮质激素
  • 万能的
  • 遗传常态

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in Percentage Total Body Fat
大体时间:Baseline and 12 months

Change in percentage total body fat measured by dual-energy X-ray absorptiometry (DXA), calculated as the 12-month value minus the baseline value and expressed in percentage points. Percentage total body fat is calculated as total fat mass divided by total body mass, multiplied by 100. Negative changes indicate a reduction in percentage total body fat. The adjusted between-cohort difference in change, defined as long-acting growth hormone minus daily recombinant human growth hormone, will be evaluated.

Baseline and 12 months

次要结果测量

结果测量
措施说明
大体时间
Change in Lean Body Mass
大体时间:Baseline and 12 months

Change in lean body mass measured by DXA, calculated as the 12-month value minus the baseline value and expressed in kilograms.

Baseline and 12 months
Change in body mass index standard deviation score (BMI-SDS)
大体时间:Baseline and 12 months

Change in age- and sex-standardized BMI-SDS from baseline to 12 months. Weight and height will be used to calculate BMI-SDS based on World Health Organization tables.

Baseline and 12 months
Change in height standard deviation score (SDS)
大体时间:Baseline and 12 months

Change in height SDS from baseline to 12 months. Height will be used to calculate BMI-SDS based on World Health Organization tables.

Baseline and 12 months
Change in Waist Circumference
大体时间:Baseline and 12 months

Change in waist circumference from baseline to 12 months, expressed in centimeters.

Baseline and 12 months
Change in Waist-to-Hip Ratio
大体时间:Baseline and 12 months

Change in waist circumference divided by hip circumference from baseline to 12 months. The ratio is dimensionless.

Baseline and 12 months
Change in Systolic Blood Pressure
大体时间:Baseline and 12 months

Change in systolic blood pressure from baseline to 12 months, expressed in mmHg.

Baseline and 12 months
Change in Diastolic Blood Pressure
大体时间:Baseline and 12 months

Change in diastolic blood pressure from baseline to 12 months, expressed in mmHg.

Baseline and 12 months
Change in Fasting Glucose Concentration
大体时间:Baseline and 12 months

Change in fasting blood glucose concentration from baseline to 12 months.

Baseline and 12 months
Change in Fasting Insulin Concentration
大体时间:Baseline and 12 months

Change in fasting blood insulin concentration from baseline to 12 months.

Baseline and 12 months
Change in HOMA-IR
大体时间:Baseline and 12 months

Change in the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), calculated from fasting glucose and insulin concentrations, from baseline to 12 months.

Baseline and 12 months
Change in Total Cholesterol Concentration
大体时间:Baseline and 12 months

Change in total cholesterol concentration from baseline to 12 months.

Baseline and 12 months
Change in LDL Cholesterol Concentration
大体时间:Baseline and 12 months

Change in LDL cholesterol concentration from baseline to 12 months.

Baseline and 12 months
Change in HDL Cholesterol Concentration
大体时间:Baseline and 12 months

Change in HDL cholesterol concentration from baseline to 12 months.

Baseline and 12 months
Change in Triglyceride Concentration
大体时间:Baseline and 12 months

Change in Triglyceride concentration from baseline to 12 months.

Baseline and 12 months
Change in Change in Carotid Intima-Media Thickness
大体时间:Baseline and 12 months

Change in carotid intima-media thickness measured bilaterally by high-resolution ultrasound at baseline and 12 months, expressed in millimeters.

Baseline and 12 months
Change in Bone Mineral Density Z-Score
大体时间:Baseline and 12 months

Change in bone mineral density Z-score measured by DXA from baseline to 12 months.

Baseline and 12 months
Change in Height Standard Deviation Score
大体时间:Baseline and 12 months

Change in height standard deviation score (height SDS) from baseline to 12 months.

Baseline and 12 months
Change in Growth Velocity Standard Deviation Score
大体时间:Baseline and 12 months

Change in growth velocity standard deviation score from baseline to 12 months.

Baseline and 12 months
Change in Bone Age Minus Chronological Age
大体时间:Baseline and 12 months

Change in the difference between bone age and chronological age from baseline to 12 months, expressed in years. Bone age will be assessed by manual reading using the Greulich and Pyle atlas.

Baseline and 12 months
Change in IGF-1 standard deviation score
大体时间:Baseline and 12 months

Change in insulin-like growth factor 1 (IGF-1) standard deviation score from baseline to 12 months.

Baseline and 12 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月1日

初级完成 (估计的)

2028年6月1日

研究完成 (估计的)

2028年6月1日

研究注册日期

首次提交

2026年11月10日

首先提交符合 QC 标准的

2026年11月10日

首次发布 (实际的)

2026年11月17日

研究记录更新

最后更新发布 (实际的)

2026年11月17日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data sharing with external researchers is not planned under the current protocol. Any future third-party data communication would require prior institutional assessment and authorization. The protocol limits such communication to aggregated data from which participants cannot reasonably be identified.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅